• Home
  1. Home
  2. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
Scientific article
English

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial

Contributors

Al-Batran, Salah-Eddin; Homann, Nils; Pauligk, Claudia; Illerhaus, Gerald; Martens, Uwe M; Stoehlmacher, Jan; Schmalenberg, Harald; Luley, Kim B; Prasnikar, Nicole; Egger, Matthias; Probst, Stephan; Messmann, Helmut; Moehler, Markus; Fischbach, Wolfgang; Hartmann, Jörg T; Mayer, Frank; Höffkes, Heinz-Gert; Koenigsmann, Michael; Arnold, Dirk; Kraus, Thomas W; Grimm, Kersten; Berkhoff, Stefan; Post, Stefan; Jäger, Elke; Bechstein, Wolf; Ronellenfitsch, Ulrich; Moenig, Stefan Paul; Hofheinz, Ralf D

Published in

JAMA oncology, vol. 3, no. 9, p. 1237-1244

Publication date

2017-09-01

First online date

2017-04-27

Abstract

KEY POINTS

Question: Is there a survival benefit for patients with limited metastatic gastric or gastroesophageal junction cancer who receive neoadjuvant chemotherapy followed by surgical resection?

Findings: In this phase 2 trial that enrolled 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma, 60 of the 238 eligible patients were classified as having limited metastatic stage and 36 of these 60 patients had surgery, including resection of the primary tumor and metastases. The median overall survival was 31.3 months for patients who underwent surgery and 15.9 months for the other patients.

Meaning: Patients with limited metastatic gastric or gastroesophageal junction cancer may benefit from neoadjuvant chemotherapy followed by surgical resection.

Keywords

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Docetaxel
  • Esophagogastric Junction
  • Fluorouracil / administration & dosage
  • Gastrectomy
  • Humans
  • Leucovorin / administration & dosage
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Lung Neoplasms / surgery
  • Lymphatic Metastasis
  • Metastasectomy
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery
  • Prospective Studies
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Survival Rate
  • Taxoids / administration & dosage
  • Young Adult

UNIGE affiliation entities

Not a UNIGE publication

Citation (ISO format)

AL-BATRAN, Salah-Eddin et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. In: JAMA oncology, 2017, vol. 3, n° 9, p. 1237–1244. doi: 10.1001/jamaoncol.2017.0515

Main files (1)

Article (Published version)

Secondary files (2)

Appendix
CC BY-NC-ND
Appendix
CC BY-NC-ND

Identifiers

Additional URL for this publication

https://jamanetwork.com/journals/jamaoncology/fullarticle/2621996

Datasets

Journal ISSN

2374-2437
220views
0downloads

Technical informations

Creation

31/01/2022 16:44:00

First validation

31/01/2022 16:44:00

Update

16/03/2023 02:35:38

Status update

16/03/2023 02:35:35

Last indexation

01/11/2024 00:46:57
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated